The Next Step In The Weight Loss Revolution
We offer compounded tirzepatide, which is similar to semaglutide as both medications work on GLP-1 (glucagon-like peptide) receptors, however, tirzepatide also works on GIP (gastric inhibitory polypeptide) receptor thus leading to up to 25% more weight loss than semaglutide.
Average weight loss with Semaglutide was 14.9% over 62 weeks, vs 20.9% with tirzepatide over 36 weeks (at the highest dose).
In addition to a greater weight reduction, compared to a placebo, tirzepatide was accompanied by greater improvements for all measured cardiovascular and metabolic risk factors such as:
- Waist circumference
- Blood pressure
- Insulin levels
- Cholesterol levels
- Liver health
Tirzepatide is administered weekly via a subcutaneous injection.
Available dosing: 2.5 mg weekly, 5 mg weekly, 7.5 mg weekly, 10 mg weekly, and 12.5 mg and 15 mg
weekly.
